Search results for "Cardiac function"

showing 10 items of 86 documents

Transient postnatal over nutrition induces long-term alterations in cardiac NLRP3-inflammasome pathway.

2018

International audience; Background and aims: The prevalence of obesity is increasing worldwide at an alarming rate. Altered early nutrition, in particular postnatal overfeeding (PNOF), is a risk factor for impaired cardiac function in adulthood. In the understanding of the initiation or progression of heart diseases, NLRP3 inflammasome and non-coding RNAs have been proposed as key players. In this context, the aim of this study was to decipher the role of NLRP3 inflammasome and its post transcriptional control by micro-RNAs in the regulation of cardiac metabolic function induced by PNOF in mice. Methods and results: Based on a model of mice exposed to PNOF through litter size reduction, we …

0301 basic medicineTime FactorsLitter SizeInflammasomesEndocrinology Diabetes and Metabolismmedicine.medical_treatmentMedicine (miscellaneous)InflammasomeOvernutritionInsulinNutrition and Dieteticsintegumentary systembiologyInflammasomeMicro-RNAsTransfection[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemAnimal Nutritional Physiological PhenomenaSignal transductionCardiology and Cardiovascular Medicinemedicine.drugSignal TransductionCardiac function curvemedicine.medical_specialtyHeart DiseasesCardiac dysfunctionsNutritional StatusContext (language use)Cell LineProto-Oncogene Protein c-ets-103 medical and health sciences[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemInternal medicineNLR Family Pyrin Domain-Containing 3 ProteinmedicineAnimalsPost-transcriptional regulationNutritionbusiness.industryInsulinMyocardiumRatsMice Inbred C57BLInsulin receptorDisease Models AnimalMicroRNAs030104 developmental biologyEndocrinologyAnimals Newbornbiology.proteinbusinessNutrition, metabolism, and cardiovascular diseases : NMCD
researchProduct

MIC trial: metoprolol in patients with mild to moderate heart failure: effects on ventricular function and cardiopulmonary exercise testing

2000

Beta-blocker therapy results in a functional benefit in patients with heart failure (CHF) due to idiopathic dilated cardiomyopathy (DCM). This study assessed if similar effects were observed in patients with ischemic heart disease (CAD), NYHA II–III after 6 months of therapy with metoprolol. Methods and results: Fifty-two patients with CHF secondary to DCM (26 patients) and CAD (26 patients) and a left ventricular ejection fraction (EF) < 40% were enrolled in the placebo-controlled study. The study medication was titrated over 6 weeks, the mean final dosage was 135 mg/day. Three patients died due to cardiogenic shock, two received placebo and one metoprolol. Eight patients did not complete …

AdultCardiomyopathy DilatedMaleCardiac function curvemedicine.medical_specialtyCardiac VolumeAdrenergic beta-AntagonistsMyocardial IschemiaCardiomyopathyVentricular Function LeftDouble-Blind MethodInternal medicineIdiopathic dilated cardiomyopathyHeart ratemedicineHumansProspective Studiescardiovascular diseasesAgedMetoprololHeart FailureEjection fractionbusiness.industryCardiogenic shockMiddle Agedmedicine.diseaseHeart failureExercise Testcardiovascular systemCardiologyFemaleCardiology and Cardiovascular Medicinebusinesshuman activitiesMetoprololcirculatory and respiratory physiologymedicine.drugEuropean Journal of Heart Failure
researchProduct

Serial echocardiographic left ventricular ejection fraction measurements: A tool for detecting thalassemia major patients at risk of cardiac death

2013

Cardiac damage remains a major cause of mortality among patients with thalassemia major. The detection of a lower cardiac magnetic resonance T2* (CMR-T2*) signal has been suggested as a powerful predictor of the subsequent development of heart failure. However, the lack of worldwide availability of CMR-T2* facilities prevents its widespread use for follow-up evaluations of cardiac function in thalassemia major patients, warranting the need to assess the utility of other possible procedures. In this setting, the determination of left ventricular ejection fraction (LVEF) offers an accurate and reproducible method for heart function evaluation. These findings suggest a reduction in LVEF≥7%, ov…

AdultMaleCardiac function curvemedicine.medical_specialtyHeart diseaseThalassemiaThalassemia major Left ventricular ejection fraction (LVEF) Chelation Echocardiography Cardiac magnetic resonance T2*Young AdultInternal medicinemedicineHumansMolecular BiologySurvival analysisModels StatisticalEjection fractionbusiness.industrybeta-ThalassemiaStroke VolumeCell BiologyHematologyStroke volumemedicine.diseaseClinical trialDeath Sudden CardiacROC CurveEchocardiographyHeart failurecardiovascular systemCardiologyMolecular MedicineFemalebusinessBlood Cells, Molecules, and Diseases
researchProduct

Reference interval determination for N-terminal-B-type natriuretic peptide (NT-proBNP): A study in blood donors

2005

We assessed reference values in a group of apparently healthy blood donors. A total of 1980 blood donors was recruited and tested for the presence of NT-proBNP using a newly developed electrochemiluminescence immunoassay (ECLIA) method. NT-proBNP clustered in all blood donors below the age of 50 years and an upper limit of normal (ULN) was found to be 84 pg/ml for males and 146 pg/ml for females. Mean NT-proBNP values increased with increasing age which was due to an increasing number of individuals exceeding the ULN. Age- and gender-appropriate NT-proBNP levels decreased with increasing hemoglobin levels. Hemoglobin but not creatinine levels influenced the NT-proBNP concentration in this c…

AdultMaleCardiac function curvemedicine.medical_specialtyLuminescenceAdolescentmedicine.drug_classClinical BiochemistryRenal functionBlood DonorsHemoglobin levelsBiochemistryHemoglobinschemistry.chemical_compoundSex FactorsReference ValuesInternal medicineNatriuretic Peptide BrainmedicineNatriuretic peptideHumanscardiovascular diseasesAgedImmunoassayCreatinineBiochemistry (medical)Age FactorsGeneral MedicineMiddle AgedPeptide FragmentsEndocrinologychemistryCreatinineReference valuesCohortFemaleHemoglobinhormones hormone substitutes and hormone antagonistsClinica Chimica Acta
researchProduct

The effect of arm-crank exercise training on power output, spirometric and cardiac function and level of autonomy in persons with tetraplegia

2019

Studies on the effects of exercise training in persons with cervical spinal cord injury (CSCI) are scarce. The aim of this study was to determine the effect of an 8-week stationary arm-crank exercise (ACE) training programme on the level of autonomy, exercise performance, pulmonary functional parameters and resting heart rate variability (HRV) in persons with CSCI. Quadriplegia Index of Function (QIF), arm-crank peak power output (Ppeak), spirometric variables, and HRV indices were measured before and after the training programme in a group of 11 persons with CSCI. ACE training increased Ppeak in both groups (

AdultMaleSpirometryCardiac function curvemedicine.medical_specialtymedia_common.quotation_subject030209 endocrinology & metabolismPhysical Therapy Sports Therapy and RehabilitationQuadriplegiaYoung Adult03 medical and health sciences0302 clinical medicinePhysical medicine and rehabilitationHeart RatemedicineHumansOrthopedics and Sports MedicinePower outputExerciseTetraplegiaSpinal Cord Injuriesmedia_commonCrankmedicine.diagnostic_testbusiness.industryRespiration030229 sport sciencesGeneral MedicineMiddle Agedmedicine.diseaseRespiratory MusclesExercise TherapyRespiratory Function TestsSpirometryCervical spinal cord injuryCervical VertebraePhysical EnduranceFemalebusinesshuman activitiesAutonomyEuropean Journal of Sport Science
researchProduct

Antihypertensive efficacy and effects of nitrendipine on cardiac and renal hemodynamics in mild to moderate hypertensive patients: Randomized control…

1992

In this study antihypertensive efficacy, safety, and the effects of short-term nitrendipine administration on central and renal hemodynamics were evaluated in mild to moderate hypertensives. Our final goal was to ascertain whether the reduction in blood pressure induced by nitrendipine treatment was associated with maintained renal function. After a run-in period with placebo, 26 hypertensives without cardiac or renal disease were randomly assigned to a double-blind 8-week controlled trial with nitrendipine (N) 20 mg once a day (13 pts) or hydrochlorothiazide (HCT) 25 mg once a day (13 pts). Renal hemodynamic measurements included effective renal plasma flow (ERPF) and glomerular filtration…

AdultMalemedicine.medical_specialtySettore MED/09 - Medicina InternaHemodynamicsRenal functionKidneyHydrochlorothiazideDouble-Blind MethodNitrendipineInternal medicinemedicineHumansPharmacology (medical)PharmacologyEjection fractionbusiness.industryNitrendipineHemodynamicsGeneral MedicineEffective renal plasma flowMiddle AgedSettore MED/11 - Malattie Dell'Apparato CardiovascolareFiltration fractionHydrochlorothiazideEndocrinologyRenal blood flowHypertensionSettore BIO/14 - FarmacologiaCardiologyFemaleCalcium channel blockers nitrendipine essential arterial hypertension cardiac function renal function.Cardiology and Cardiovascular Medicinebusinessmedicine.drugCardiovascular Drugs and Therapy
researchProduct

Improving the preclinical models for the study of chemotherapy-induced cardiotoxicity: a Position Paper of the Italian Working Group on Drug Cardioto…

2015

Although treatment for heart failure induced by cancer therapy has improved in recent years, the prevalence of cardiomyopathy due to antineoplastic therapy remains significant worldwide. In addition to traditional mediators of myocardial damage, such as reactive oxygen species, new pathways and target cells should be considered responsible for the impairment of cardiac function during anticancer treatment. Accordingly, there is a need to develop novel therapeutic strategies to protect the heart from pharmacologic injury, and improve clinical outcomes in cancer patients. The development of novel protective therapies requires testing putative therapeutic strategies in appropriate animal model…

Cardiac function curveACE inhibitorsCardiotonic AgentsNeuregulin-1CardiomyopathyAntineoplastic AgentsPreclinical modelsCardioprotectionCardiotonic AgentsPharmacologyBioinformaticsmedicine.disease_causeCancer therapy-induced cardiac injury ;Preclinical modelsMitochondria HeartBeta-blockersNeoplasmsCancer therapy-induced cardiac injuryMedicineAnimalsHumansCardiac stem cellsCardioprotectionCardiotoxicityACE inhibitors; Beta-blockers; Cancer therapy-induced cardiac injury; Cardiac stem cells; Cardioprotection; Mitochondria; Neuregulin-1; Oxidative stress; Preclinical models; Statinsbusiness.industryStatinsCancermedicine.diseaseCardiotoxicityMitochondriaCancer therapy-induced cardiac injury Preclinical models Cardioprotection Mitochondria Neuregulin-1 Oxidative stress Statins Beta-blockers ACE inhibitors Cardiac stem cellsDisease Models AnimalOxidative StressHeart failureCardiology and Cardiovascular MedicinebusinessOxidative stress
researchProduct

Agalsidase alpha and hearing in Fabry disease: data from the Fabry Outcome Survey.

2006

Fabry disease is an X-linked lysosomal storage disorder characterized by multi-organ dysfunction, including hearing loss - mainly sensorineural. The recent introduction of enzyme replacement therapy (ERT) has resulted in improvements in renal and cardiac function, pain and quality of life. One study has also suggested small improvements in high-frequency hearing. In this paper, we study the effect of ERT on hearing in patients in the Europe-wide database - the Fabry Outcome Survey (FOS). Twenty-six patients in FOS had pure-tone audiometry performed up to 6 months before starting ERT with agalsidase alpha and after a median of 12 months of treatment. We assessed changes in hearing thresholds…

Cardiac function curveAdultMalemedicine.medical_specialtyHearing lossClinical BiochemistryAlpha (ethology)AudiologyBiochemistryQuality of lifeotorhinolaryngologic diseasesmedicineHumansLongitudinal Studiesmedicine.diagnostic_testbusiness.industryVascular diseaseGeneral MedicineEnzyme replacement therapymedicine.diseaseFabry diseaseSurgeryIsoenzymesTreatment OutcomeSensory Thresholdsalpha-GalactosidaseAudiometry Pure-ToneFabry DiseaseFemalemedicine.symptomAudiometrybusinessEuropean journal of clinical investigation
researchProduct

Prognostic significance of central venous-to-arterial carbon dioxide difference during the first 24 hours of septic shock in patients with and withou…

2017

IF 6.238; International audience; Objective: To investigate the prognostic significance of central venous-to-arterial carbon dioxide difference (cv-art CO2 gap) during septic shock in patients with and without impaired cardiac function.Methods: We performed a prospective cohort study in 10 French intensive care units. Patients suffering from septic shock were assigned to the impaired cardiac function group (‘cardiac group’, n=123) if they had atrial fibrillation (AF) and/or left ventricular ejection fraction (LVEF) 0.9 kPa at 12 h had a higher risk of day 28 mortality (hazard ratio=3.18; P=0.0049). Among the 59 patients in the cardiac group with mean arterial pressure (MAP) ≥65 mm Hg, centr…

Cardiac function curveAdultMalemedicine.medical_specialtyMean arterial pressureAdolescentCentral Venous Pressurecentral venous-arterial CO2 difference030204 cardiovascular system & hematologyVentricular Function Left03 medical and health sciencesYoung Adult0302 clinical medicine[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathologyInternal medicineIntensive caremedicineHumansArterial PressureProspective StudiesAgedEjection fractionbusiness.industrySeptic shockCentral venous pressure030208 emergency & critical care medicineCarbon DioxideMiddle Agedmedicine.diseasePrognosisShock Septic3. Good healthSurgeryAnesthesiology and Pain MedicineBlood pressureblood gas analysisCardiologyArterial bloodseptic shockFemalebusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

Epicardial Fat, Cardiac Geometry and Cardiac Function in Patients with Nonalcoholic Fatty Liver Disease: Association with the Severity of Liver Disea…

2015

Background & Aims Non-alcoholic fatty liver disease (NAFLD) has been associated with increased cardiovascular risk, including coronary artery disease and cardiac dysfunction. In addition, recent evidence highlighted the possible role of epicardial fat as a new cardiometabolic risk factor. We tested the correlation between epicardial fat, alterations in cardiac geometry and function, and severity of liver damage, in patients with biopsy-proven NAFLD. Methods The anthropometric, biochemical and metabolic features were recorded in 147 consecutive biopsy-proven NAFLD cases (Kleiner score). Epicardial fat thickness was measured by echocardiography. Results Epicardial fat was higher in patients w…

Cardiac function curveAdultMalemedicine.medical_specialtySettore MED/09 - Medicina InternaStatistics as TopicDiastoleEPICARDIAL FATSettore MED/08 - Anatomia PatologicaSeverity of Illness IndexCoronary artery diseaseLiver diseaseFibrosisNon-alcoholic Fatty Liver DiseaseRisk FactorsNASH; NAFLD; EPICARDIAL FAT; CARDIAC DYSFUNCTION;Internal medicineNAFLDmedicineHumansSettore MED/12 - GastroenterologiaEjection fractionHepatologybusiness.industryFatty liverNASHHeartMiddle Agedmedicine.diseaseEndocrinologyLiverCardiovascular DiseasesEchocardiographyCardiologyFemaleSteatohepatitisbusinessPericardiumCARDIAC DYSFUNCTION
researchProduct